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1. Introduction 
Drug attrition that occurs in late clinical development or during post-marketing is a serious 
economic problem in the pharmaceutical industry (1). The cost for drug approvals is 
approaching $1 billion USD, and the cost of advancing a compound to Phase 1 trials can 
reach up to $100 million USD according to the Tufts Center for the Study of Drug 
Development, Tufts University School of Medicine (2). The study also estimates a $37,000 
USD direct out-of-pocket cost for each day a drug is in the development stage and 
opportunity costs of $1.1 million USD in lost revenue (2). Given these huge expenditures, 
substantial savings can accrue from early recognition of problems that would demonstrate a 
compound’s potential to succeed in development (3).  
The costs associated with withdrawing a drug from the market are even greater. For 
example, terfenadine is both a potent hERG cardial channel ligand and is metabolized by the 
liver enzyme Cyp3A4. Terfenadine was frequently co-administered with Cyp3A4 inhibitors 
ketoconazole or erythromycin (4). The consequent overload resulted in increases in plasma 
terfenadine to levels that caused cardiac toxicity (5) resulting in the drug to be withdrawn 
from the market (6) at an estimated cost of $6 billion USD. Another example is the broad-
spectrum antibiotic trovafloxacin, which was introduced in 1997 and soon became Pfizer’s 
top seller. The drug was metabolically activated in vivo and formed a highly reactive 
metabolite causing severe drug-induced hepatotoxicity (7). Trovafloxacin was black labeled 
in 1998 (8) costing Pfizer $8.5 billion USD in lawsuits (9). With the new ability to measure 
hERG and other important ADMET (Absorption, Distribution, Metabolism, Excretion and 
Toxicity) parameters early in the discovery and development process, such liabilities are 
now recognized earlier allowing for safer analogs to be advanced to more expensive formal 
preclinical and clinical stages. 
The purpose of preclinical ADMET also referred to as early DMPK (drug metabolism and 
pharmacokinetics) is to reduce the risk similar to above and avoid spending scarce resources 
on weak lead candidates and programs. This allows drug-development resources to be 
focused on fewer, but more-likely-to-succeed drug candidates. In 1993, 40 % of drugs failed 
in clinical trials because of pharmacokinetic (PK) and bioavailability problems (10). Since 
then, major technological advances have occurred in molecular biology and screening to 
allow major aspects of ADMET to be assessed earlier during the lead-optimization stage. By 
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the late 1990s the pharmaceutical industry recognized the value of early ADMET assessment 
and began routinely employing it with noticeable results. ADME and DMPK problems 
decreased from 40% to 11% (4). Presently, a lack of efficacy and human toxicity are the 
primary reasons for failure (11).  
The terms “drugability” and “druglikeness” were first described by Dr. Christopher 
Lipinski, who proposed “Lipinski’s Rule of 5” due to the frequent appearance of a number 
“5” in the rules (12). The Rule of 5 has come to be a compass for the drug discovery industry 
(13). It stipulates that small-molecule drug candidates should possess: 
 a molecular weight less than 500 g/mol 
 a partition coefficient (logP – a measure of hydrophobicity) less than 5 
 no more than 5 hydrogen bond donors 
 no more than 10 hydrogen bond acceptors  
A compound with fewer than three of these properties is unlikely to become a successful 
orally bioavailable drug. There are exceptions to Lipinski’s Rule of 5 that have become 
marketed drugs, such as those taken up by active transport mechanisms, natural 
compounds, oligonucleotides and proteins. 
The drug discovery industry is experiencing dramatic structural change and is no longer 
just the domain of traditional large pharmaceutical companies. Now venture-capital-funded 
startups, governments, venture philanthropy and other non-profit and academic 
organizations are important participants in the search for new drug targets, pathways, and 
molecules. These organizations frequently form partnerships, sharing resources, capabilities, 
risks and rewards of drug discovery. Thus, it is becoming increasingly important to ensure 
that investors, donors, and taxpayers’ money is efficiently used so that new safe drugs for 
unmet medical needs may be delivered to the public. ADMET profiling has been proven to 
remove poor drug candidates from development and accelerate the discovery process.  
Although lack of efficacy and unexpected toxicity are the major causes of drug failure in 
clinical trials, a prime determinant is the ability of a drug to penetrate biological barriers 
such as cell membranes, intestinal walls, or the blood brain barrier (BBB). For drugs that 
target the Central Nervous System (CNS) such as stroke, in vitro efficacy combined with the 
inability to penetrate the BBB typically result in poor in vivo efficacy in patients. The 
delivery of systemically administered drugs to the brain of mammals is limited by the BBB 
as it effectively isolates the brain from the blood because of the presence of tight junctions 
connecting the endothelial cells of the brain vessels. In addition, specific metabolizing 
enzymes and efflux pumps such as P-glycoprotein (P-gp) and the multi-drug-resistance 
protein (MRP), located within the endothelial cells of the BBB, actively pump exogenous 
molecules out of the brain (14, 15). This is one of the reasons for CNS drugs having a 
notoriously high failure rate (16). In recent years, 9% of compounds that entered Phase 1 
survived to launch and only 3-5% of CNS drugs were commercialized (16). Greater than 
50% of this attrition resulted from failure to demonstrate efficacy in Phase 2 studies. Over 
the last decade, Phase 2 failures have increased by 15%. Compounds with demonstrated 
efficacy against a target in vitro and in animal models frequently proved to be ineffective in 
humans. Many of these failures occur due to the inability to reach the CNS targets such as in 
stroke due to lack of BBB permeability. For drugs targeted to reduce damage from a stroke, 
the delivery method, BBB permeability, and drug metabolism and clearance can provide life 
or death to a patient if the drug is not delivered to the target tissue in its active form in a 
matter of hours from the event. 
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Due to the extraordinary cost of drug development, it is highly desirable to have effective, 
cost-efficient and high-throughput tools to measure BBB permeability before proceeding to 
expensive and time consuming animal BBB permeability studies or human clinical trials. 
With in vitro tools available, promising drug candidates with ineffective BBB penetration 
may be improved by removing structural components that mediate interaction(s) with 
efflux proteins, and/or lowering binding to brain tissue at earlier stages of development to 
increase intrinsic permeability (17).  
The development of drugs targeting CNS requires precise knowledge of the drug’s brain 
penetration. Ideally, this information would be obtained as early as possible to focus 
resources on compounds most likely to reach the target organ. The physical transport and 
metabolic composition of the BBB is highly complex. Numerous in vitro models have been 
designed to study kinetic parameters in the CNS, including non-cerebral peripheral 
endothelial cell lines, immortalized rat brain endothelial cells, primary cultured bovine, 
porcine or rat brain capillary endothelial cells and co-cultures of primary brain capillary 
cells with astrocytes (18, 19, 20). In vitro BBB models must be carefully assessed for their 
capacity to reflect accurately the passage of drugs into the CNS in vivo. 
Alternatively, several in vivo techniques have been used to estimate BBB passage of drugs 
directly in laboratory animals. In vivo transport across the BBB was first studied in the 1960s 
using the early indicator diffusion method (IDM) of Crone (21). Other in vivo techniques 
were later proposed including brain uptake index (BUI) measurement (22), in situ brain 
perfusion method (23, 24), autoradiography and intracerebral microdialysis (25). 
Unfortunately these methods have limitations including sophisticated equipment, technical 
expertise, mathematical modeling, species differences, invasiveness, and low throughput 
and render them unsuitable for use during early stages of drug discovery and development. 
Hence, in vitro and in vivo models remain mere approximations of the complex BBB and 
their relevance to human pharmacology must be carefully considered. The most appropriate 
method to conduct controlled experiments is to cross-compare the BBB passage of a series of 
compounds evaluated with both in vitro and in vivo models. This enables cross-correlations 
of pharmacokinetic data and the assessment of the predictive power of in vitro and in vivo 
tests. 
2. The evolving science of ADMET 
Regulatory authorities have relied upon in vivo testing to predict the behavior of new 
molecules in the human body since the 1950s. Bioavailability, tissue distribution, 
pharmacokinetics, metabolism, and toxicity are assessed typically in one rodent and one 
non-rodent species prior to administering a drug to a human to evaluate safety in a clinical 
trial (Phase 1). Biodistribution is assessed using radioactively labeled compounds later in 
development because it is expensive both in terms of synthesizing sufficient amounts of 
radioactively labeled compound and for performing the animal experiments (22).  
Pharmacodynamic (PD) effectiveness of test compounds is typically assessed initially 
through in vitro models such as receptor binding, followed by confirmation through in vivo 
efficacy models in mice or rats. The predictive ability depends on the therapeutic area and 
the animal model. Infectious disease models are considered to have the best predictive 
ability, whereas CNS and oncology animal models are generally the least predictive of 
human efficacy. Understanding the PK/PD relationship is crucial in determining the 
mechanism of action and metabolic stability of the molecule which can explain and support 
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efficacy results. In vivo pharmacokinetic (PK) studies in a variety of animal models are 
routinely used for lead optimization to assess drug metabolism and absorption. There are 
significant differences in absorption and metabolism among species from animal studies, 
which may cause conflicting predictions of degradation pathways of new chemical entities 
(NCEs).  
Toxicity and safety studies are performed in models that are relevant to the NCE’s mode of 
action and therapeutic area. In vivo toxicity models are required for IND (Investigational 
New Drug Application) to the US Food and Drug Administration, but have substantial 
predictive weaknesses. In a retrospective study of 150 compounds from twelve large 
pharmaceutical companies, the combined animal toxicity study of rodents and non-rodents 
accurately predicted only 50% of the human hepatotoxicity. This poor level of accuracy in 
animal toxicity studies caused large numbers of compounds to be removed from 
development without proceeding into clinical trials with the potential of demonstrating 
safety in human subjects (26). The other ~50% whose toxicity could not be predicted was 
attributed to “idiosyncratic human hepatotoxicity that cannot be detected by conventional 
animal toxicity studies”. Although it is widely recognized that mechanisms for toxicity are 
frequently quite different between species, animal testing remains the “gold standard” for 
required regulatory and historical data reasons. The US FDA and other regulatory agencies 
are in the process of evaluating alternatives to animal testing, with the aim of developing 
models that are truly predictive of human mechanisms of toxicity, and limiting in vivo 
toxicology testing. 
3. The ADMET feedback loop 
As discussed above, historically ADMET studies were focused on in vivo assays. These are 
time- and resource-intensive, and generally low throughput assays resulting in their 
implementation later in the development process, when more resources are released to 
study the few molecules that have advanced to this stage. With the advent of in vitro high-
throughput screening, molecular biology and miniaturization technologies in the 1990s, 
early ADMET assays were developed to predict in vivo animal and human results, at a level 
of speed and cost-effectiveness appropriate for the discovery stage. This produced a major 
advance in the science of ADMET and has created a new paradigm that drug discovery 
programs follow in advancing compounds from hit to lead, from lead to advanced lead, and 
on to nominated clinical candidates. Now, early in the discovery phase, using human 
enzymes and human-origin cells, drug discovery programs are able to obtain highly 
actionable information about the drug-likeness of new molecules, the potential to reach 
target organ, and early indications of known human mechanisms of toxicities. ADMET 
assessment of varying complexity is currently routinely performed on compounds that have 
shown in vitro efficacy and in conjunction with or just prior to demonstrating early proof of 
principle in vivo.  
The application of early ADMET is unique to each drug discovery program. The 
development path from discovery to IND is not straightforward and is dependent on the 
therapeutic area, route of administration, chemical series, and other parameters. 
Correspondingly, the importance of the various ADMET assays is based upon the specifics 
of the drug discovery program. ADMET assays can also be categorized into those that are 
routine and those reserved for more advanced profiling.  This division is also a function of 
cost effectiveness and the need for the specific information. For instance, data regarding 
www.intechopen.com
 
De-Risking Drug Discovery Programmes Early with ADMET 
 
279 
induction of human liver enzymes and transporters are not relevant during the hit-to-lead 
phase and is normally obtained for fewer more advanced candidates.  
In some cases the FDA requests data from in vitro ADMET assays. For example, in vitro 
drug-drug interaction (DDI) studies may now be conducted under the guidance from FDA 
dated September 2006. The guidance document precisely outlines methods to conduct CYP-
450 inhibition and induction and P-gp interaction studies (27). This package is now typically 
included in an IND submission. 
How should a discovery team employ early ADMET? The answer is not simple and 
formulaic  it is a process. It is useful to start from the ultimate goal and work backwards 
towards discovery. The drug discovery and development team should first define the target 
product profile (TPP), which includes indication, intended patient population, route of 
administration, acceptable toxicities, and ultimately will define the drug label. The TPP 
invariably will evolve during the life of the project, but having major parameters of TPP 
established initially maintains a collaboration and focus between disciplines such as biology 
and chemistry, discovery and development, pre-clinical and clinical groups. Once the TPP is 
identified, then major design elements of the Phase 2 and 3 clinical trials can be outlined 
leading to questions about the tolerability, toxicity and safety of the molecule. These 
parameters will then define the GLP toxicity studies in animals, which will guide the team 
to the discovery and preclinical development data to be addressed in an early ADMET 
program.  
How is this information implemented in the discovery phase? If a compound has high target 
receptor binding and biological activity in cells and in relevant in vivo animal models, what 
are the chances of it becoming a successful drug? A molecule needs to cross many barriers to 
reach its biological target. In order to obtain this goal, a molecule must be in solution and 
thus the first step is typically to assess the solubility of a compound. A solubility screen 
provides information about the NCE’s solubility in fluids compatible with administration to 
humans. Chemical and metabolic stability is a further extension of the intrinsic properties of 
a molecule. Chemical stability in buffers, simulated gastric and intestinal fluids, and 
metabolic stability in plasma, hepatocytes or liver microsomes of different species can be 
measured to predict the rate of decay of a compound in the different environments 
encountered in the human body.  
The second step is to define the absorption properties and the bioavailability of a molecule. 
Measurement of permeability across Caco-2 cell monolayers is a good predictor of human 
oral bioavailability. For CNS drugs, assessment of BBB penetration would be performed at 
this stage and is usually a key component of lead optimization campaigns. Passive BBB 
permeability may be assessed using BBB-PAMPA assays whereas potential for active uptake 
or efflux may be determined using in vivo models or cell lines naturally expressing 
endogenous human intestinal or BBB transporters (such as CaCO-2 cell line) or cell lines 
overexpressing specific transporters (such as MDCK-MDR1).  
Measurement of binding to plasma proteins indicates the degree of availability of the free 
compound in the blood circulation. This is critical as only unbound drugs are able to reach 
the target and exert their pharmacologic effects. Metabolism and drug-drug interaction 
issues are discovered by screening for inhibition of cytochrome P450 liver enzymes 
(CYP450). All these assays allow chemists and biologists to obtain actionable information 
and provide a link between structure-activity (SAR) and structure-properties (SPR) 
relationships that drive decisions on selection of chemical series and molecules.  
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The next step is the involvement of drug-drug interactions and is required for advanced 
lead optimization. The effect of drug transporters on permeability and the effect of drugs on 
transporter activity can be measured in Caco-2, MDCK-MDR1 or other models. P-gp 
interactions are particularly important for CNS drugs due to high expression of these efflux 
transporters in the human BBB. Early knowledge about these interactions is instrumental to 
the medicinal chemistry strategy and helps drive lead optimization.  
The effect of a compound on CYP-450 metabolism can be identified by determining the 50% 
inhibitory concentration (IC50) for each CYP-450. These relationships between the NCE and 
metabolizing enzymes need to be evaluated in the context of the human effective dose and 
maximum effective plasma concentrations. These human data are not normally available at 
early stages of discovery, but could be extrapolated from animal PK/PD results for 
compounds in more advanced stages of development. It is important to understand these 
transporter and CYP-450 relationships for the following.  
1. The compound may affect the effective plasma concentrations of other concomitantly 
administered drugs if metabolized by the same CYPs (i.e., terfenadine).  
2. If the parent drug is a CYP inducer, it may increase the clearance rate of concomitantly 
administered drugs which are metabolized by these CYPs. This may result in a decrease 
in these drugs’ effective plasma concentrations, thus decreasing their pharmacologic 
effect.  
3. Metabolites formed via CYP metabolism may be responsible for undesirable side effects 
such as organ toxicity.  
4. The metabolite of a compound may actually be responsible for compound’s efficacy, 
and not the parent compound. The metabolite may even have a better efficacy, safety, 
and pharmacokinetics profile than its parent. As a result, metabolism can be exploited 
to produce a better drug which will impact the medicinal chemistry strategy.  
5. The identification of drug-metabolizing enzymes involved in the major metabolic 
pathways of a compound assists to predict the probable drug-drug interactions in 
humans. This information also may be used to design human clinical trials to detect 
unnecessary drug-drug interaction. 
ADMET is a tool that supports overall program goals. Similar to the Rule of 5 that requires 
only 3 of the 4 conditions to be met, seldom will negative results from a single ADMET 
assay terminate a compound’s development or the overall program. The results are more 
likely to alter the medicinal chemistry direction.  
After assessing compounds in a few simple mechanistic systems such as plasma and liver 
microsomal stability screens in relevant species, lead optimization phase is started that 
includes assays which identify potential liabilities. Finally, at the stage of advanced lead 
optimization and development, more-complex systems are used to more thoroughly 
understand a compound’s metabolic fate and absorption mechanism to drive efficient 
development. As ADMET roadblocks are discovered, the cycle is repeated until a clear path 
is found (Figure 1). 
4. Impact of ADMET  
Early ADMET provides the data necessary for selecting preclinical candidates by providing 
crucial information to medicinal chemists and accelerates the timelines for IND and 
subsequently NDA submission which translates to lengthier commercialization under 
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patent protection and greater profits. For investors, this is a major parameter. For 
philanthropic organizations and from standpoint of public policy, it means increasing the 
time of clinical benefit to the public. Data compiled by the Tufts Center for Drug Discovery 
have identified that for a typical, moderately successful proprietary drug ($350 million USD 
annual sales) each day’s delay equates to $1.1 million USD in lost patent protected revenues 
that provide the return on investment needed to fund drug discovery (3). Further, shorter 
discovery and development timelines provide faster liquidity events for venture capital and 
angel investors. As drug discovery requires a longer commercialization than any other form 
of product development, its slowness to produce returns is a major impediment for 
obtaining investment. Accelerating drug discovery and development should attract more 
investment in drug discovery research. 
 
ADMET Feedback Loop
ADMET is a tool that supports program goals
One ADMET assay is not going kill a compound
Start from simple mechanistic systems
Support lead optimization on few assays important for the series
Advanced lead optimization/development
As ADMET roadblocks discovered, repeat the loop
 
Fig. 1. ADMET Feedback Loop. 
ADMET technologies remain an active area of research. There are many challenges in 
accurately measuring BBB penetration which may be one of the reasons for poor human 
efficacy of CNS drug candidates. Another challenge is detection of all mechanisms of human 
idiosyncratic toxicity. These mechanisms cause the most expensive, harmful, and 
disheartening form of drug attrition – post-commercialization toxicity. Many idiosyncratic 
drug reactions are due to formation of short-lived reactive metabolites that bind covalently 
to cell proteins (28). The extent to which a compound will generate these metabolites can 
now be detected before a compound is administered to humans signifying progress. Other 
mechanisms of human toxicity can be observed early in discovery and are briefly described 
in the following section.  
5. New ADMET tools 
Penetrating the BBB is a challenge particular to CNS drug discovery. Another obstacle 
caused by BBB permeability is that many drugs not intended as CNS therapeutics cause 
neurotoxicity. Artificial membrane permeability assays (PAMPA and BBB-PAMPA) offer a 
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cost-effective and high-throughput method of screening for passively absorbed compounds 
but do not predict active transport in or out of the brain.  
5.1 In Vitro model of human adult Blood-Brain Barrier 
Many new drugs designed for CNS may show exceptional therapeutic promise due to their 
high potency at the target site, but lack general efficacy when administered systemically. In 
many cases, the problem is due to lack of penetration of the BBB and this has become a 
major problem that has impeded the discovery and development of active CNS drugs. CEA 
Technologies previously reported the development of a new co-culture-based model of 
human BBB able to predict passive and active transport of molecules into the CNS (29). This 
new model consists of primary cultures of human brain capillary endothelial cells co-
cultured with primary human glial cells (18, 29). The advantages of this system include: 
i. made of human primary culture cells 
ii. avoids species, age and inter-individual differences since the two cell types are 
removed from the same person 
iii. expresses functional efflux transporters such as P-gp, MRP-1, 4,5 and BCRP.  
This model has potential for assessment of permeability of drug and specific transport 
mechanisms, which is not possible in PAMPA or other cell models due to incomplete 
expression of active transporters. 
One important step in development of any in vitro model is to cross-correlate in vitro and in 
vivo data in order to validate experimental models and to assess the predictive power of the 
techniques (30). The human BBB model was validated against a “gold standard” in vivo 
model and has shown an excellent in vitro-in vivo correlation (29, 31). In this carefully 
designed in vivo-in vitro correlation study the authors reported the evaluation of the BBB 
permeabilities for a series of compounds studied correlatively in vitro using a human BBB 
model and in vivo with quantitative PET imaging (29). Six clinical PET tracers with different 
molecular size ranges (Figure 2) and degree of BBB penetration were used including [18F]-
FDOPA and [18F]-FDG, ligands of amino acid and glucose transporters, respectively. The 
findings demonstrate that the in vitro co-culture model of human BBB has important 
features of the BBB in vivo including low paracellular permeability, well developed tight 
junctions, functional expression of important known efflux transporters and is suitable for 
discriminating between CNS and non-CNS compounds. To further demonstrate the 
relevance of the in vitro human system, drug permeation into the human brain was 
evaluated using PET imaging in parallel to the assessment of drug permeability across the in 
vitro model of the human BBB. In vivo plasma - brain exchange parameters used for 
comparison were determined previously in humans by PET using a kinetic analysis of the 
radiotracer binding. 2-[18F]Fluoro-A-85380 and [11C]-raclopride show absent or low cerebral 
uptake with the distribution volume under 0.6. [11C]-Flumazenil, [11C]-befloxatone, [18F]-
FDOPA and [18F]-FDG show a cerebral uptake with the distribution volume above 0.6. The 
in vitro human BBB model discriminates compounds similar to in vivo human brain PET 
imaging analysis. This data illustrates the close relationship between in vitro and in vivo 
pharmacokinetic data (r2 0.90, p < 0.001) (Figure 2). Past in vivo-in vitro studies often did not 
have good correlations for substances transported into or out of the brain via active 
transport. Presumably this is due to experiments being performed either with models that 
did not have adequate expression of active human transporters (such as PAMPA or MDCK 
cells) or using too high concentrations of compounds in vitro, which are known to saturate 
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the transporters. Using the radioactive labeled probes and the small amounts of compounds 
avoids these issues. 
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A. Chemical structures of radioligands investigated and used clinically. 
 
[11C]Befloxatone
0.4
0
min-1
[18F]-F-A-85380
B
 
B. Typical imaging data. Co-registered PET-MRI images representing the k1 obtained in 
human after intravenous injection of [11C]-Befloxatone (left) and [18F]-F-A-85380 (right). The 
PET images representing the k1 are as follows: PET image obtained at 1 min post injection 
(mean value between 30 sec and 90 sec) is considered as independent to the receptor binding. 
This image (in Bq/mL) is corrected from the vascular fraction (Fv in Bq/mL, considered as 4% 
of the total blood concentration at 1 min) and divided by the arterial plasma input function 
(AUC0-1 min of the plasma concentration, in Bq*min/mL). The resulting parametric image, 
expressed in min-1, represent an index of the k1 parameter of the radiotracer. 
Fig. 2. In vitro-in vivo drug transport correlation. 
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C. In Vivo Distribution Volume (DV) as function of the in vitro Pe-out/Pe-in ratio (Q). 
Regression line was calculated, and correlation was estimated by the two tailed non 
parametric Spearman test. [11C]PE2I radioligand was not plotted in the figure since the in 
vivo K1/k2 parameter in human is not available. 
Fig. 2. In vitro-in vivo drug transport correlation (continued). 
In conclusion, this in vitro human BBB model offers great potential for both being developed 
into a reproducible screen for passive BBB permeability and determining active transport 
mechanisms. Due to its high-throughput potential, the model may provide testing large 
numbers of compounds of pharmaceutical importance for CNS diseases. Validation work is 
in progress in which activity of transporters that are important in CNS BBB are being 
assessed in a functional assay and compared between CaC0-2 and hBBB models (31). 
5.2 Mechanisms of human toxicity 
Idiosyncratic hepatotoxicity or drug-induced liver injury (DILI) occurs in only one out of 
about 10,000 patients and is usually statistically impossible to discover during clinical trials. 
In spite of its name which means “rare event with undefined mechanism”, some 
mechanisms have now been defined including mitochondrial toxicity and the formation of 
reactive metabolites. Another mechanism of human toxicity that is not limited to the liver, 
but may also affect lung, spleen, and heart tissues is phospholipidosis.  
5.2.1 Mitochondrial toxicity 
Mitochondrial toxicity is increasing implicated in drug-induced idiosyncratic toxicity. Many 
of the drugs that have been withdrawn from the market due to organ toxicity have been 
found to be mitochondrial toxicants (32). Mitochondrial toxicants injure mitochondria by 
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inhibiting respiratory complexes of the electron chain, inhibiting or uncoupling oxidative 
phosphorylation, inducing mitochondrial oxidative stress, or inhibiting DNA replication, 
transcription, or translation (33).  
Toxicity testing of drug candidates is usually performed in immortalized cell lines that have 
been adapted for rapid growth in a reduced-oxygen atmosphere. Their metabolism is often 
anaerobic by glycolysis despite having functional mitochondria and an adequate oxygen 
supply. Alternatively, normal cells generate ATP for energy consumption aerobically by 
mitochondrial oxidative phosphorylation. The anaerobic metabolism of transformed cell 
lines is less sensitive to mitochondrial toxicants causing systematically underreporting in 
toxicity testing (33, 34). To address this issue, HepG2 and NIH/3T3 cells can be grown in 
media in which glucose is replaced by galactose (32). The change in sugar results in the 
metabolism of the cell to possess a respiratory substrate that is both more similar to normal 
cells and sensitive to mitochondrial toxicants without reducing sensitivity to non-
mitochondrial toxicants (Figure 3). 
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Fig. 3. Effect of Antimycin A, a compound known to be toxic to mitochondria (A) and 
Imipramine (B) on parent HepG2 cells (Mito-R - blue) and a HepG2 cell line that has been 
developed to become sensitive to mitochondrial toxicants (Mito-S - red). 
5.2.2 Reactive metabolites formation 
Another property of compounds that can cause idiosyncratic toxicity is their ability to form 
reactive intermediates (35). Formation of short-lived reactive metabolites is known to be the 
mechanism of toxicity of some compounds such as acetaminophen (36). The formation of 
reactive metabolites can be identified by incubating test compounds with liver microsomes 
and adding glutathione to trap the reactive intermediates which are then identified by 
LC/MS/MS (Figure 4). Conversion of more than 10% of the test agent to reactive 
intermediates indicates that the compound may be implicated in idiosyncratic toxicity.  
5.2.3 Phospholipidosis 
Phospholipidosis is a lysosomal storage disorder and can be caused by drugs that are 
cationic amphiphiles (37). The disorder is considered to be mild and often can self-resolve. 
However, drugs that cause phospholipidosis can also produce organ damage, and thus this 
disorder is a concern to the regulatory agencies (37). A cell-based assay for phospholipidosis 
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has been developed (38) which involves accumulation of a fluorescent phospholipid 
resulting in an increase of fluorescence in the lysosomes of cells that have been treated with 
drugs that cause phospholipidosis (Figure 5). If phospholipidosis is absent, the 
phospholipid is degraded and fluorescence does not increase. Increases in fluorescence are 
normalized to cell numbers since many of these drugs are also cytotoxic (Figure 5).  
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Fig. 4. Formation of Reactive Metabolites of Acetaminophen. Acetaminophen was incubated 
with microsomes and glutathione in the presence and absence of NADPH. An adduct of 
glutathione with acetaminophen was formed in the presence of NADPH. When NADPH 
was absent (No Reaction Control), no adduct was formed. 
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Fig. 5. Drug-induced phospholipidosis (PLD) is determined by measuring the accumulation 
of a fluorescent phospholipid in cells treated with increasing drug concentrations. 
Fluorescence is measured and normalized to cell number. Fluorescence is increased in cells 
treated with compounds that are known to cause PLD (chlorpromazine, tamoxifen, 
amiodarone), but it is not increased in cells treated with a compound that is known not to 
cause PLD (acetaminophen). 
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5.2.4 High-content toxicology: The present and future of predictive toxicology 
Drug safety is a major concern for the pharmaceutical industry with greater than 30% of 
drug candidates failing in clinical trials as a result of toxicity (3, 10). Furthermore, there are 
numerous examples of drugs which have been withdrawn from the market or given black 
box warnings as a result of side effects not identified in clinical trials. Developing and 
commercializing a drug is a large financial commitment and failure at this stage can be 
catastrophic for a company. To address this problem, there has been a significant drive to 
incorporate toxicity assessment at much earlier stages in the drug discovery and 
development process. 
It is well recognized that animal models are often not reflective of human toxicity. This is 
corroborated by a large percentage of drugs fail in the clinic through toxicity despite having 
progressed through costly preclinical animal studies. Human hepatotoxicity, as well as 
hypersensitivity and cutaneous reactions, are particularly difficult to identify during 
regulatory-based animal studies. Only 50% of drugs found to be hepatotoxic in clinical 
studies showed concordance with animal toxicity results (39, 40). In addition, there are 
profound ethical issues associated with the widespread use of animals for this purpose. 
Initiatives such as ECVAM, ICCVAM and NC3Rs are currently addressing this problem by 
identifying alternatives to animal safety testing. The cosmetics industry is at the forefront 
and starting in 2013 there is an anticipated total EU ban of the sale of cosmetics tested on 
animals. 
The introduction of more relevant and sophisticated in vitro human systems is essential to 
overcome these issues and will enable higher throughput screening assays to be 
implemented earlier and more cost effectively. The widespread use of in vitro methods has 
to some extent been hampered by their relatively poor predictive capability as traditionally 
only single markers of toxicity have been investigated. However, in many cases, drug 
toxicity is a highly complex process which can manifest itself via multiple different 
mechanisms. Predictions of toxicity can only be improved by investigating a broad panel of 
markers and their relationship to each other. 
6. The power of high content screening 
Technologies such as high content screening (HCS) have transformed cell biology and 
enabled subtle changes in multiple cellular processes to be tracked within the same cell 
population and well. The technique uses either fluorescently labeled antibodies or dyes to 
stain specific areas of the cell which have critical roles in cell health or the maintenance of 
cellular function. The impact of concentration-dependent and time-dependent drug 
exposure on these cellular processes can be investigated and related to specific toxicological 
or efficacious responses. The ability to analyze multiple end points simultaneously, yet 
selectively, is a major advantage and as well as being more sensitive, allows greater 
predictivity and an improved mechanistic understanding over traditional single endpoint 
measurements (41). 
The power of HCS in toxicity assessment was illustrated in two key papers authored by 
scientists at Pfizer (41, 42) where a panel of 6 to 8 key toxicity markers were identified and 
used to predict human hepatotoxicity. The articles highlight the improved predictive power 
of HCS over existing conventional in vitro toxicity assays and over traditional preclinical 
animal tests. HCS technology is now routinely used for in vitro toxicity assessment in large 
pharmaceutical companies. 
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7. CellCiphr
TM
 – bridging the gap between in vitro and in vivo 
It is critical to link the in vitro HCS information to animal or human pathology and establish 
a relationship to the in vivo data. The patterns observed in the key toxicity markers are often 
characteristic of specific mechanisms of known pathology.  
The CellCiphrTM system utilizes the powerful technique of HCS and combines this with a 
novel classifier system which is underpinned by a large database of information for drugs 
with known toxicological profiles. Using this system the toxicological profiles generated by 
HCS can be compared with known drugs for which animal or clinical data are available. 
Specific changes in cellular function observed for particular mechanisms of toxicity can then 
be recognized and used to predict for unknown NCEs. 
It is well recognized that toxicological events can be organ specific, time-dependent and 
concentration-dependent. The CellCiphrTM system investigates three different panels which 
represent general cytotoxicity (using HepG2 cells) or organ specific toxicity (using primary 
rat hepatocytes as a model for hepatotoxicity or H9c2 cardiomyocytes as a model for 
cardiotoxicity). The panels have been validated for the most relevant parameters for each 
particular cell type. Depending on the panel, these include the following cell health 
parameters: cell cycle arrest, nuclear size, oxidative stress, stress kinase activation, DNA 
damage response, DNA fragmentation, mitochondrial potential and mass, mitosis marker, 
cytoskeletal disruption, apoptosis, steatosis, phospholipidosis, ROS generation, hypertrophy 
and general cell loss. To assess early and late stage toxic responses, CellCiphrTM investigates 
exposure at 3 different time points. Dose dependent effects are investigated by exposing the 
cells to 10 different concentrations of the compound. 
Data are represented as AC50 (concentration at which average response is 50% of control 
activity) for each cell health parameter, and the collection of AC50 values over the entire cell 
feature set comprises the response profile. Proprietary visual and quantitative data mining 
tools including CellCiphrTM Classifiers, correlation analysis and cluster analysis are used to 
analyze the profiles (Figure 6). Using the CellCiphrTM approach, there are a number of 
different ways by which the data can be interpreted. 
1. Similarity profile plots can identify potential mechanisms of actions by correlating 
unknown test compound response with known control compounds where the 
mechanisms of action are already known. 
2. The relative toxicity of compounds in a series can be predicted by the CellCiphrTM 
Classifier and used to rank compounds for prioritization of the most promising 
candidates.  
3. The most potent or earliest cellular response can be extracted from the data which may 
highlight the optimal endpoint(s) for designing higher throughput systems to 
investigate SAR within a series. 
Detailed mechanistic data can be generated for specific compounds. In the case of nimesulide 
which has been withdrawn from the market for severe hepatotoxicity, the CellCiphrTM 
Hepatotoxicity Profiling Panel scored this drug as the most toxic of the nonsteroidal anti-
inflammatory drugs (NSAIDS). The toxicity was associated with a specific mechanistic profile 
characterized by an early oxidative stress response captured as a decreased mitochondrial 
membrane potential after 1 hour of exposure. This insult drives the development of an 
apoptotic response at subsequent times points measured in the release of cytochrome C from 
the mitochondria and activation of the DNA damage response. Finally, prolonged exposure to 
nimesulide is marked by the accumulation of lipids in lysosomes and other vesicles (Figure 7). 
The early effect on cell loss may also indicate a necrotic response in addition to apoptosis. 
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Fig. 6. The CellCiphrTM system uses HCS imaging platforms to identify specific patterns of 
biomarker response following exposure to multiple concentrations of compound at multiple 
time points. Proprietary visual and quantitative data mining tools have been developed to 
analyse the profiles and compare unknown compound response against known in vivo 
pathology. 
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Fig. 7. Nimesulide, which has been withdrawn from the market in several countries over 
concerns of severe hepatotoxicity, was scored as the most toxic of the NSAIDS by the 
CellCiphrTM Hepatotoxicity Profiling Panel. The toxicity is associated with a specific 
mechanistic profile at sub-lethal doses.  
7.1 Future strategies 
In summary, CellCiphrTM is shown here as an example of a novel approach which identifies 
time dependent, sub-lethal effects on cell health and function. The system illustrates significant 
improvements over existing single end point assays and has the ability to predict mechanistic 
outcomes by correlating with known compound profiles and pathology. By expanding the 
CellCiphrTM database, improving bioinformatics platform and increasing the number of panels 
to cover new organ specific cells, it will continue to improve the reliability of the classification. 
Toxicological response is influenced by many factors including dose administration 
(including tissue exposure levels), time of exposure and/or accumulation in specific cells. 
Many of these factors are influenced by the pharmacokinetics of the drug administered and 
its effect on absorption, distribution, metabolism and excretion. Considering ADME data in 
conjunction with multiparametric measurements of in vitro toxicology is likely to be an 
important consideration in the future direction of predictive toxicology. Incorporation of 
human PK parameters prediction in models such as CellCiphr to ensure that cytotoxicity is 
relevant to projected tissue exposure is actively being pursued.  
8. Genotoxicity  
Genotoxicity of drugs is an important concern to the regulatory authorities. The FDA 
recommends a number of in vitro and in vivo tests to measure the mutagenic potential of 
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chemical compounds, including the Ames test in Salmonella typhimurium (43). GreenScreen 
GC, a new, high-throughput assay that links the regulation of the human GADD45a gene to 
the production of Green Fluorescent Protein (GFP) has become available. The assay relies on 
the DNA damage-induced up-regulation of the RAD54 gene in yeast measured using a 
promoter-GFP fusion reporter (44). The test is more specific and sensitive for genotoxicity 
than those currently recommended by the FDA such as the Ames and mouse lymphoma 
tests. 
9. Current challenges and future directions 
A large amount of progress in the field of ADMET profiling has occurred in the last 15 
years. This progress has decreased the proportion of drug candidates failing in clinical trials 
for ADME reasons providing optimism in an otherwise declining productivity in drug 
discovery. The principal barrier now is the toxicity portion of ADMET. The prediction of 
human-specific toxicology must be improved. 
Cell-based assays using established cell lines and co-cultures have been used to determine 
toxicity to various organs, but many of these cell lines have lost some of the physiological 
activities present in normal cells. HepG2 cells, for instance, have greatly reduced levels of 
metabolic enzymes. Primary human hepatocytes can be used but are expensive, suffer from 
high donor-to-donor variability, and maintain their characteristics for only a short time. Three-
dimensional models have been developed for cell-based therapies including micropatterned 
co-cultures of human liver cells that maintain the phenotypic functions of the human liver for 
several weeks (45). This development should provide more accurate information about toxicity 
when used in ADMET screening and could be extended to other organ-specific cells leading to 
integrated tissue models in the “human on a chip” (46). The potential of stem cells to 
differentiate into cell lines of many different lineages may be exploited to develop human and 
animal stem-cell-derived systems for major organ systems (47).  
High content screening (HCS) has been used for early cytotoxicity measurement since 2006 
and provides great optimism (41). This method has been optimized for hepatocytes and is 
more predictive of hepatotoxicity than other currently available methods and in the future 
could be applied to cells of other organs. 
Molecular profiling is another alternative and is defined as any combination or individual 
application of mRNA expression, proteomic, toxicogenomic, or metabolomic measurements 
that characterize the state of a tissue (48). This approach has been applied in an attempt to 
develop profiles or signatures of certain toxicities. Molecular profiles, in conjunction with 
agents that specifically perturb cellular systems, have been used to identify patterns of 
changes in gene expression and other parameters at sub-toxic drug concentrations that 
might be predictive of hepatotoxicity including idiosyncratic hepatotoxicity (49). In the 
future, larger data sets, high-throughput gene disruptions, and more-diverse profiling data 
will lead to more-detailed knowledge of disease pathways and will facilitate in target 
selection and the construction of detailed models of cellular systems for use in ADMET 
screening to identify toxic compounds early in the discovery process. The combination of in 
silico, in vitro, and in vivo methods and models into multiple content data bases, data mining, 
and predictive modeling algorithms, visualization tools, and high-throughput data-analysis 
solutions can be integrated to predict systems’ ADMET properties. Such models are starting 
to be built and should be widely available within 10 years (50). The use of these tools will 
lead to a greater understanding of the interactions of drugs with their targets and predict 
their toxicities.  
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To conclude, the future should provide a decrease in late-stage development failures and 
withdrawals of marketed drugs, faster timelines from discovery to market, and reduced 
development costs through the reduction of late-stage failures. 
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